Monograph
M01AX05 - Glucosamine |
Not porphyrinogenic |
NP |
Rationale
No CYP-dependent metabolism.
Chemical description
Relatively small and water-soluble molecule (MW 179)
Therapeutic characteristics
Endogenous substance that possibly works by a positiv influence on cartilage metabolism. Common adverse reactions that can be mistaken for porphyria symptoms are dyspepsia, stomach ache, diarrhoea, constipation, nausea.
Hepatic exposure
Significant
Metabolism and pharmacokinetics
Metabolized mainly by the hexosamine-system and thereby independent of the cytopchrome P-450 system (1).
Preclinical data
None
Personal communication
None
Published experience
None
IPNet drug reports
Uneventful use reported in 28 patients with acute porphyria.
References
| # |
Citation details |
PMID |
|---|
| * | Summary of Product Characteristics |
| 1. |
1) SPC glucosamine (updated: 2007-12-20).
|
|
Similar drugs
Tradenames and packages
From some sources, we get a list of packages (United Kingdom, Ireland, Estonia).
Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway).
What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names
are the searchable terms. The gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
Netherlands
Belgium
United Kingdom
Denmark
Norway
Poland
Luxembourg
Iceland
Finland
Latvia
Serbia
